Methods comprising apoptosis inhibitors for the generation of transgenic pigs |
 |
|
|
||||||||||||||||||||||||||||||||||||||||||
| Title: | Chimeric chains for receptor-associated signal transduction pathways |
| Inventors: | Capon, Daniel J.; Hillsborough, CA, USA Weiss, Arthur; Mill Valley, CA, USA Irving, Brian A.; San Francisco, CA, USA Roberts, Margo R.; San Francisco, CA, USA Zsebo, Krisztina; Woodside, CA, USA |
| Summary: | This invention describes a novel chimeric DNA encoding chimeric proteins for receptor-associated signal transduction pathways. Described herein are chimeric proteins and DNA sequences encoding the proteins which are characterized by an extracellular domain capable of binding to a ligand in a non-MHC restricted manner, a transmembrane domain and a cytoplasmic domain capable of activating a signaling pathway. Further disclosed are properties of the extracellular domain and cytoplasmic domain which are described as not naturally occurring together. Claims of the invention include the transduction of a signal and activation of a signaling pathway within the cell as a result of the ligand binding, whereby the cell may be induced to carry out various functions relating to the signaling pathway. Also provided are methods by which either natural or synthetic extracellular domains may be employed as receptors. Therapeutic applications are included for the use of such chimeric DNA sequences in the modification of lymphocytes and hematopoietic stem cells in the treatment of a variety of diseases. |
| Abstract: | Chimeric proteins and DNA sequence encoding chimeric proteins are provided, where the chimeric proteins are characterized by an extracellular domain capable of binding to a ligand in a non-MHC restricted manner, a transmembrane domain and a cytoplasmic domain capable of activating a signaling pathway. The extracellular domain and cytoplasmic domain are not naturally found together. Binding of ligand to the extracellular domain results in transduction of a signal and activation of a signaling pathway in the cell, whereby the cell may be induced to carry out various functions relating to the signalling pathway. A wide variety of extracellular domains may be employed as receptors, where such domains may be naturally occurring or synthetic. The chimeric DNA sequences may be used to modify lymphocytes as well as hematopoietic stem cells as precursors to a number of important cell types. |
| US Patent Website: | Click Here for Full Text of Patent |
| Title Number: | US5359046 |
| Application Number: | US1992000988194 |
| Date Filed: | 09/12/1992 |
| Date Published: | 25/10/1994 |
| Assignee: | Cell Genesys, Inc., Foster City, CA, USA The Regents of the University of California, Oakland, CA, USA |